



Code: 532 321

Listing Department BSE LIMITED P J Towers, Dalal Street, Fort, <u>Mumbai – 400 001</u>

Code: CADILAHC

Listing Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated February 11, 2020 titled "Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.


Thanking you,

Yours faithfully, For, CADILA HEALTHCARE LIMITED

OlyAou

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%.

Ahmedabad, 11 February, 2020

Zydus Cadila has received the final approval from the USFDA to market Fluocinonide Cream USP, (US RLD - Vanos Cream) 0.1%. The drug is used to treat a variety of skin conditions (e.g., psoriasis, eczema, dermatitis, allergies, rash) and will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 279 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

For further information please contact : The Corporate Communications Department Cadila Healthcare Limited Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India. Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com CIN : L24230GJ1995PLC025878